Literature DB >> 10212126

Chicoric acid analogues as HIV-1 integrase inhibitors.

Z Lin1, N Neamati, H Zhao, Y Kiryu, J A Turpin, C Aberham, K Strebel, K Kohn, M Witvrouw, C Pannecouque, Z Debyser, E De Clercq, W G Rice, Y Pommier, T R Burke.   

Abstract

The present study was undertaken to examine structural features of L-chicoric acid (3) which are important for potency against purified HIV-1 integrase and for reported cytoprotective effects in cell-based systems. Through a progressive series of analogues, it was shown that enantiomeric D-chicoric acid (4) retains inhibitory potency against purified integrase equal to its L-counterpart and further that removal of either one or both carboxylic functionalities results in essentially no loss of inhibitory potency. Additionally, while two caffeoyl moieties are required, attachment of caffeoyl groups to the central linking structure can be achieved via amide or mixed amide/ester linkages. More remarkable is the finding that blockage of the catechol functionality through conversion to tetraacetate esters results in almost no loss of potency, contingent on the presence of at least one carboxyl group on the central linker. Taken as a whole, the work has resulted in the identification of new integrase inhibitors which may be regarded as bis-caffeoyl derivatives of glycidic acid and amino acids such as serine and beta-aminoalanine. The present study also examined the reported ability of chicoric acid to exert cytoprotective effects in HIV-infected cells. It was demonstrated in target and cell-based assays that the chicoric acids do not significantly inhibit other targets associated with HIV-1 replication, including reverse transcription, protease function, NCp7 zinc finger function, or replication of virus from latently infected cells. In CEM cells, for both the parent chicoric acid and selected analogues, antiviral activity was observable under specific assay conditions and with high dependence on the multiplicity of viral infection. However, against HIV-1- and HIV-2-infected MT-4 cells, the chicoric acids and their tetraacetylated esters exhibited antiviral activity (50% effective concentration (EC50) ranging from 1.7 to 20 microM and 50% inhibitory concentration (IC50) ranging from 40 to 60 microM).

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10212126     DOI: 10.1021/jm980531m

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  14 in total

1.  Identification and synthesis of a kairomone mediating host location by two parasitoid species of the cassava mealybug Phenacoccus herreni.

Authors:  P A Calatayud; J Auger; E Thibout; S Rousset; A M Caicedo; S Calatayud; H Buschmann; J Guillaud; N Mandon; A C Bellotti
Journal:  J Chem Ecol       Date:  2001-11       Impact factor: 2.626

2.  Preliminary mapping of a putative inhibitor-binding pocket for human immunodeficiency virus type 1 integrase inhibitors.

Authors:  Deborah J Lee; W Edward Robinson
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

Review 3.  Targeting Metalloenzymes for Therapeutic Intervention.

Authors:  Allie Y Chen; Rebecca N Adamek; Benjamin L Dick; Cy V Credille; Christine N Morrison; Seth M Cohen
Journal:  Chem Rev       Date:  2018-09-07       Impact factor: 60.622

4.  Rapid activity prediction of HIV-1 integrase inhibitors: harnessing docking energetic components for empirical scoring by chemometric and artificial neural network approaches.

Authors:  Patcharapong Thangsunan; Sila Kittiwachana; Puttinan Meepowpan; Nawee Kungwan; Panchika Prangkio; Supa Hannongbua; Nuttee Suree
Journal:  J Comput Aided Mol Des       Date:  2016-06-17       Impact factor: 3.686

5.  Specific inhibition of human immunodeficiency virus type 1 (HIV-1) integration in cell culture: putative inhibitors of HIV-1 integrase.

Authors:  N Vandegraaff; R Kumar; H Hocking; T R Burke; J Mills; D Rhodes; C J Burrell; P Li
Journal:  Antimicrob Agents Chemother       Date:  2001-09       Impact factor: 5.191

6.  Structural basis for the recognition between HIV-1 integrase and transcriptional coactivator p75.

Authors:  Peter Cherepanov; Andre L B Ambrosio; Shaila Rahman; Tom Ellenberger; Alan Engelman
Journal:  Proc Natl Acad Sci U S A       Date:  2005-10-31       Impact factor: 11.205

7.  Identification of an inhibitor-binding site to HIV-1 integrase with affinity acetylation and mass spectrometry.

Authors:  Nick Shkriabai; Sachindra S Patil; Sonja Hess; Scott R Budihas; Robert Craigie; Terrence R Burke; Stuart F J Le Grice; Mamuka Kvaratskhelia
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-26       Impact factor: 11.205

8.  An allosteric mechanism for inhibiting HIV-1 integrase with a small molecule.

Authors:  Jacques J Kessl; Jocelyn O Eidahl; Nikolozi Shkriabai; Zhuojun Zhao; Christopher J McKee; Sonja Hess; Terrence R Burke; Mamuka Kvaratskhelia
Journal:  Mol Pharmacol       Date:  2009-07-28       Impact factor: 4.436

9.  Light-enhanced caffeic acid derivatives biosynthesis in hairy root cultures of Echinacea purpurea.

Authors:  Bilal H Abbasi; Chun-Long Tian; Susan J Murch; Praveen K Saxena; Chun-Zhao Liu
Journal:  Plant Cell Rep       Date:  2007-03-30       Impact factor: 4.570

10.  Azido-containing diketo acid derivatives inhibit human immunodeficiency virus type 1 integrase in vivo and influence the frequency of deletions at two-long-terminal-repeat-circle junctions.

Authors:  Evguenia S Svarovskaia; Rebekah Barr; Xuechun Zhang; Godwin C G Pais; Christophe Marchand; Yves Pommier; Terrence R Burke; Vinay K Pathak
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.